All In Biotech

Drug Trial Radar · NCT00050934

Pediatric Epilepsy Study

A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.

Last checked: Nov 19, 2026Latest source record: Nov 23, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

132

Actual

Start

Jun 2002

Primary completion

Jun 2004

Study completion Jun 2004

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 1, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Who can join
All sexes, from 1 month, up to 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.

Conditions

  • Epilepsy
  • Epilepsies, Partial

Interventions

  • oxcarbazepineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline)

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Madera, California

  • Site not named

    Orange, California

  • Site not named

    Wilmington, Delaware

  • Site not named

    Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Duluth, Minnesota

  • Site not named

    Saint Paul, Minnesota

  • Site not named

    Chesterfields, Missouri

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Akron, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Fort Worth, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Norfolk, Virginia

  • Brigadeiro Hospital

    Sao Paulo - SP, Brazil

  • Site not named

    Kehl-Kork, Germany

  • Site not named

    Kiel, Germany

  • Novartis

    Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.